Literature DB >> 24145171

Increased risk for respiratory syncytial virus-associated, community-acquired alveolar pneumonia in infants born at 31-36 weeks of gestation.

David Greenberg1, Ron Dagan, Eilon Shany, Jacob Bar-Ziv, Noga Givon-Lavi.   

Abstract

BACKGROUND: We compared hospitalization and pediatric intensive care unit (PICU) admission rates for community-acquired alveolar pneumonia (CAAP) and respiratory syncytial virus (RSV)-associated CAAP (RSV-CAAP) in non-RSV-immunized children <24-month-old born at 31-36 weeks gestational age (GA) versus those born at term (>36 weeks GA).
METHODS: Nasopharyngeal samples for RSV were obtained prospectively (2004-2011) during RSV season, from hospitalized children with radiographic-diagnosed CAAP. Soroka University Medical Center is the only hospital in the region, enabling population-based rate calculation. Relative risks (RR) and 95% confidence intervals (95% CI) were calculated comparing RSV-CAAP incidence in 31-36 weeks GA with >36 weeks GA children.
RESULTS: CAAP hospitalization incidences (per 1000 population) were 23.6 and 9.4 (RR: 2.52; 95% CI: 2.13-2.68), respectively; the respective incidences of PICU admission for overall CAAP were 1.8 and 0.2 (RR: 7.88; 95% CI: 4.59-11.83). The RRs (and 95% CI) for RSV-CAAP hospitalizations and PICU admission rates were (after extrapolation) 15.2 and 5.8 (RR: 2.79; 95% CI: 2.31-3.06) and 1.1 and 0.1 (RR: 9.14; 95% CI: 4.93-16.96), respectively. In a multiregression analysis in patients with RSV-CAAP versus CAAP, 31-36 weeks GA was an independent risk factor for hospitalization (RR: 1.485; 95% CI: 1.03-2.14).
CONCLUSIONS: Children <24-month-old born at 31-36 weeks GA are at increased risk for hospitalization and PICU admission for both overall CAAP and RSV-associated CAAP compared with those born at >36 weeks GA. Moreover, in late premature children, RSV represented a 50% increased risk for CAAP compared with infants born at term.

Entities:  

Mesh:

Year:  2014        PMID: 24145171     DOI: 10.1097/INF.0000000000000130

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  4 in total

1.  Recent Developments in Pediatric Community-Acquired Pneumonia.

Authors:  Russell J McCulloh; Karisma Patel
Journal:  Curr Infect Dis Rep       Date:  2016-05       Impact factor: 3.725

2.  Should we use Palivizumab immunoprophylaxis for infants against respiratory syncytial virus? - a cost-utility analysis.

Authors:  Gary M Ginsberg; Eli Somekh; Yechiel Schlesinger
Journal:  Isr J Health Policy Res       Date:  2018-12-17

3.  Characterization of children younger than 5 Years of age with severe community-acquired alveolar pneumonia (CAAP) requiring Pediatric Intensive Care Unit (PICU) admission.

Authors:  Yael Feinstein; David Greenberg; Shalom Ben-Shimol; Maya Mimran; Ron Dagan; Noga Givon-Lavi
Journal:  Pediatr Neonatol       Date:  2020-04-10       Impact factor: 2.083

4.  Comparison of health care resource utilization among preterm and term infants hospitalized with Human Respiratory Syncytial Virus infections: A systematic review and meta-analysis of retrospective cohort studies.

Authors:  Sebastien Kenmoe; Cyprien Kengne-Nde; Abdou Fatawou Modiyinji; Giuseppina La Rosa; Richard Njouom
Journal:  PLoS One       Date:  2020-02-21       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.